|
Synonyms: AVE-1642 | AVE1642 | Lumvoa®: | veligrotug-vvze | VRDN-001
veligrotug is an approved drug
Compound class:
Antibody
Comment: Veligrotug (AVE-1642) is a monoclonal antibody that targets insulin-like growth factor 1 receptor (IGF1R) [4].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| No information available. |
Summary of Clinical Use ![]() |
| Veligrotug (AVE-1642) was progressed as a clinical lead, initially for anti-tumour potential [2,8,10]. In a change of direction the antibody was further evaluated as a treatment for autoimmune thyroid eye disease (TED) [3]. The US FDA approved veligrotug as a treatment for TED in June 2026 [7]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05176639 | A Safety, Tolerability and Efficacy Study of Veligrotug (VRDN 001) in Healthy Volunteers and Participants With Thyroid Eye Disease (TED) ( THRIVE ) | Phase 3 Interventional | Viridian Therapeutics, Inc. | 11 | |
| NCT06021054 | An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED) (THRIVE-2) | Phase 3 Interventional | Viridian Therapeutics, Inc. | ||
| NCT06179875 | An Open-label Study (OLE) for Non-responders of VRDN-001-101 (NCT05176639) and VRDN-001-301 (NCT06021054) | Phase 3 Interventional | Viridian Therapeutics, Inc. | ||
| NCT01233895 | Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma | Phase 1 Interventional | Sanofi | ||